CARDINAL HEALTH INC Form 8-K/A June 07, 2001

1

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K/A (AMENDMENT NO. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 14, 2001

Cardinal Health, Inc.
------(Exact name of registrant as specified in its charter)

7000 Cardinal Place, Dublin, Ohio 43017
------(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (614) 757-5000

2

Item 5. Other Events

On February 14, 2001, Cardinal Health, Inc., an Ohio corporation (the "Registrant"), completed its merger (the "Bindley Merger") of a wholly owned subsidiary of the Registrant ("Sub") with and into Bindley Western Industries, Inc. ("Bindley"). Bindley was the surviving corporation of the Bindley Merger and is now a wholly owned subsidiary of the Registrant. Pursuant to the Agreement and Plan of Merger dated as of December 2, 2000, by and among the Registrant, Sub and Bindley (the "Bindley Merger Agreement"), each outstanding share of Bindley common stock was converted into 0.6413 of a common share of the Registrant (the "Bindley Exchange Ratio"). Pursuant to the terms of the Bindley Merger Agreement, approximately 23.1 million common shares of the Registrant ("Common Shares") were issued in exchange for Bindley common stock and Bindley's outstanding stock options were converted into options to purchase approximately

5.1 million common shares.

. The restated consolidated financial statements of the Registrant, filed in connection with this report, give effect to the Bindley Merger which was accounted for as a pooling-of-interests business combination.

Item 7. Financial Statements and Exhibits

- (a) Consolidated financial statements of the Registrant and Bindley prepared under the pooling-of-interests method of accounting:
 - INDEPENDENT AUDITORS' REPORTS
 - FINANCIAL STATEMENTS AND SCHEDULE

Consolidated Statements of Earnings for the Fiscal Years Ended June 30, 2000, June 30, 1999 and June 30, 1998 Consolidated Balance Sheets at June 30, 2000 and June 30, 1999 Consolidated Statements of Shareholders' Equity for the Fiscal Years Ended June 30, 2000, June 30, 1999 and June 30, 1998

Consolidated Statements of Cash Flows for the Fiscal Years Ended June 30, 2000, June 30, 1999 and June 30, 1998

Notes to Consolidated Financial Statements Schedule II - Valuation and Qualifying Accounts

- MANAGEMENT'S DISCUSSION AND ANALYSIS
- SELECTED CONSOLIDATED FINANCIAL DATA

The foregoing are included in Annex A to this Form 8-K.

- (c) Exhibits

 - 23.01 Consent of Arthur Andersen LLP
 - 23.02 Consent of Deloitte & Touche LLP
 - 23.03 Consent of Arthur Andersen LLP
 - 23.04 Consent of PricewaterhouseCoopers LLP
 - 23.05 Consent of PricewaterhouseCoopers LLP
 - 99.01 Statement Regarding Forward-Looking Information. (2)

- (1) Included as an exhibit to the Registrant's Registration Statement on Form S-4 (No. 333-53394) and incorporated herein by reference.
- (2) Filed as an exhibit to the Quarterly Report on Form 10-Q of the Registrant (File No. 0-12591) for the quarter ended December 31, 2000, and incorporated herein by reference.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARDINAL HEALTH, INC.

June 6, 2001

By: /s/ Richard J. Miller

Richard J. Miller Executive Vice President and Chief Financial Officer

3

4

REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS

To the Shareholders and Directors of Cardinal Health, Inc.:

We have audited the accompanying consolidated balance sheet of Cardinal Health, Inc. and subsidiaries as of June 30, 2000 and the related consolidated statements of earnings, shareholders' equity and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We did not audit the historical consolidated financial statements of Bindley Western Industries, Inc. (Bindley), a wholly owned subsidiary of Cardinal Health, Inc., as of December 31, 1999 and for the year then ended. The historical consolidated financial

statements of Bindley represent approximately 15% of consolidated total assets at June 30, 2000, and represent total revenues and net income of approximately 22% and 5%, respectively, of consolidated amounts for the year then ended. These consolidated financial statements were audited by another auditor whose report, presented herein, and our opinion, insofar as it relates to the amounts included for Bindley, is based solely on the report of such auditor.

We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit and the report of the other auditor provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Cardinal Health, Inc. and subsidiaries as of June 30, 2000 and the consolidated results of their operations and their cash flows for the year then ended in conformity with accounting principles generally accepted in the United States.

The consolidated financial statements of Cardinal Health, Inc. and subsidiaries for the years ended June 30, 1999 and 1998, prior to restatement for pooling of interests, and the separate financial statements of Bindley for the years ended December 31, 1998 and 1997 that have been included in the June 30, 1999 and 1998 restated consolidated financial statements of Cardinal Health, Inc., were audited and reported on separately by other auditors and whose reports, presented herein a) dated August 10, 1999, except for the first sentence of the fourth paragraph of Note 2 as to which the date is May 26, 2000 and the fiscal 1999 and 1998 amounts in Note 12 as to which the date is September 5, 2000 and b) dated March 21, 2000, except as to the revision to the financial statements to account for the business combination with Central Pharmacy Services, Inc. as a purchase rather than a pooling of interests and the second paragraph of Note 16 to the consolidated financial statements of Cardinal Health, Inc., which are as of December 15, 2000, respectively expressed unqualified opinions on those statements. We audited the combination of the accompanying consolidated balance sheet as of June 30, 1999 and the related consolidated statements of earnings, shareholders' equity and cash flows for each of the years in the two-year period then ended, after restatement for the fiscal 2001 pooling of interests. In our opinion, such consolidated statements have been properly combined on the basis described in Note 1 of the notes to consolidated financial statements.

/s/ Arthur Andersen LLP

ARTHUR ANDERSEN LLP Columbus, Ohio June 6, 2001

4

5

REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS ON FINANCIAL STATEMENT SCHEDULE

To the Shareholders and Directors of Cardinal Health, Inc.:

Our audit of the consolidated financial statements referred to in our report dated June 6, 2001 appearing on page 4 of this Form 8-K/A also included an audit of the information as of and for the year ended June 30, 2000 in the Financial Statement Schedule - Valuation and Qualifying Accounts. We did not audit the historical Financial Statement Schedule of Bindley Western Industries, Inc. (Bindley), a wholly owned subsidiary of Cardinal Health, Inc., as of December 31, 1999 and for the year then ended. This Financial Statement Schedule was audited by another auditor whose report, presented herein, and our opinion, insofar as it relates to the amounts included for Bindley, is based solely on the report of such auditor.

The Financial Statement Schedule of Cardinal Health, Inc. for the years ended June 30, 1999 and 1998, prior to the restatement for pooling of interests, and the separate Financial Statement Schedule of Bindley for the years ended December 31, 1998 and 1997, that have been included in the June 30, 1999 and 1998 restated consolidated Financial Statement Schedule, were audited and reported on separately by other auditors whose reports, presented herein a) dated August 10, 1999, except for the first paragraph of Note 2 as to which the date is May 26, 2000 and the fiscal 1999 and 1998 amounts in Note 12 as to which the date is September 5, 2000 and b) dated March 21, 2000, except as to the revision to the financial statements to account for the business combination with Central Pharmacy Services, Inc. as a purchase rather than a pooling of interests and the second paragraph of Note 16 to the consolidated financial statements of Cardinal Health, Inc., which are as of December 15, 2000, respectively expressed unqualified opinions on that schedule. We audited the combination of the information for each of the two years in the period ended June 30, 1999, after restatement for the 2001 pooling of interests.

In our opinion, this Financial Statement Schedule presents fairly, in all material respects, the information set forth therein as of and for the year ended June 30, 2000 when read in conjunction with the related consolidated financial statements, and, in our opinion, the information for each of the two years in the period ended June 30, 1999, has been properly combined on the basis described in Note 1 of the Notes to Consolidated Financial Statements.

/s/ Arthur Andersen LLP

ARTHUR ANDERSEN LLP Columbus, Ohio June 6, 2001

5

6

INDEPENDENT AUDITORS' REPORT

To the Shareholders and Directors of Cardinal Health, Inc.:

We have audited the consolidated balance sheet of Cardinal Health, Inc. and subsidiaries as of June 30, 1999, and the related consolidated statements of earnings, shareholders' equity, and cash flows for each of the two years in the period ended June 30, 1999. Our audits also included the consolidated financial statement schedule, as it relates to the years ended June 30, 1999 and 1998, listed in the Index at Item 7. The consolidated financial statements and financial statement schedule audited by us were prior to the restatement for the 2001 pooling of interests with Bindley Western Industries, Inc. (Bindley) as

described in Note 2 of the consolidated financial statements. These consolidated financial statements and consolidated financial statement schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements and consolidated financial statement schedule based on our audits. We did not audit the financial statements of Allegiance Corporation ("Allegiance"), a wholly owned subsidiary of Cardinal Health, Inc., as of June 30, 1999, and for the years ended June 30, 1999 and 1998. We also did not audit the financial statements of R.P. Scherer Corporation ("Scherer"), a wholly owned subsidiary of Cardinal Health, Inc., as of June 30, 1999, and for years ended June 30, 1999 and March 31, 1998. The combined financial statements of Allegiance and Scherer represent approximately 44% of consolidated total assets at June 30, 1999, and represent combined revenues and net income of approximately 25% and 28% and 35% and 39%, respectively, of consolidated amounts for each of the two years in the period ended June 30, 1999. These statements were audited by other auditors whose reports have been furnished to us, and our opinion, insofar as it relates to the amounts included for Allegiance and Scherer, is based solely on the reports of such other auditors.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluating the overall financial statement presentation. We believe that our audits and the reports of other auditors provide a reasonable basis for our opinion.

In our opinion, based on our audits and the reports of the other auditors, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Cardinal Health, Inc. and subsidiaries at June 30, 1999, and the results of their operations and their cash flows for each of the two years in the period ended June 30, 1999 in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, such consolidated financial statement schedule, as it relates to the years ended June 30, 1999 and 1998, when considered in relation to the basic fiscal 1999 and 1998 consolidated financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

/s/ Deloitte & Touche LLP

DELOITTE & TOUCHE LLP

Columbus, Ohio

August 10, 1999, except for the first sentence of the fourth paragraph of Note 2 as to which the date is May 26, 2000 and the fiscal 1999 and 1998 amounts in Note 12 as to which the date is September 5, 2000.

REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS

To R.P. Scherer Corporation:

We have audited the accompanying consolidated statement of financial position of R.P. SCHERER CORPORATION (a Delaware corporation and a wholly-owned subsidiary of Cardinal Health, Inc.) and subsidiaries as of June 30, 1999 and the related consolidated statements of income, comprehensive income, cash flows and shareholders' equity for the year ended June 30, 1999 and the year ended March 31, 1998 (not presented separately herein). These financial statements and the schedule referred to below are the responsibility of the company's management. Our responsibility is to express an opinion on these financial statements and this schedule based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of R.P. Scherer Corporation and subsidiaries as of June 30, 1999, and the results of their operations and their cash flows for the year ended June 30, 1999 and for the year ended March 31, 1998, in conformity with accounting principles generally accepted in the United States.

Our audits were made for the purpose of forming an opinion on the basic financial statements taken as a whole. The schedule of valuation allowances is presented for purposes of complying with the Securities and Exchange Commission's rules and is not a required part of the basic financial statements (not presented separately herein). This schedule has been subjected to the auditing procedures applied in our audits of the basic financial statements and, in our opinion, is fairly stated in all material respects in relation to the basic financial statements taken as a whole.

/s/Arthur Andersen LLP

Roseland, New Jersey August 9, 1999

REPORT OF INDEPENDENT ACCOUNTANTS

To the Stockholders of Allegiance Corporation

In our opinion, the consolidated balance sheet and the related consolidated statements of operations, of cash flows and of equity of Allegiance Corporation and its subsidiaries (not presented separately herein) present fairly, in all material respects, the financial position of Allegiance Corporation, a wholly-owned subsidiary of Cardinal Health Inc., and its subsidiaries at June 30, 1999, and the results of their operations and their cash flows for the years ended June 30, 1999 and 1998, in conformity with generally accepted accounting principles. These financial statements are the responsibility of Allegiance Corporation's management; our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with generally accepted auditing standards, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for the opinion expressed above.

/s/ PricewaterhouseCoopers LLP

PRICEWATERHOUSECOOPERS LLP Chicago, Illinois July 29, 1999

8

9

REPORT OF INDEPENDENT ACCOUNTANTS ON FINANCIAL STATEMENT SCHEDULE

To the Stockholders of Allegiance Corporation

Our audits of the consolidated financial statements of Allegiance Corporation and its subsidiaries referred to in our report dated July 29, 1999 appearing on page 8 of the Cardinal Health, Inc. Current Report on Form 8-K/A dated February

14, 2001 also included an audit of the Financial Statement Schedule II - Valuation and Qualifying Accounts ("Financial Statement Schedule") of Allegiance Corporation and its subsidiaries (not presented separately herein). In our opinion, this Financial Statement Schedule presents fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated financial statements.

/s/ PricewaterhouseCoopers LLP

PRICEWATERHOUSECOOPERS LLP

Chicago, Illinois July 29, 1999

9

10

REPORT OF INDEPENDENT ACCOUNTANTS

To the Board of Directors and Shareholders of Bindley Western Industries, Inc.:

In our opinion, the consolidated balance sheets and the related consolidated statements of earnings, shareholders' equity and cash flows of Bindley Western Industries, Inc. and its subsidiaries (the "Company"), (not presented separately herein) present fairly, in all material respects, their financial position at December 31, 1999 and 1998, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 1999, prior to adjustments related to the 2001 pooling of interests with Cardinal Health, Inc., in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company's management; our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and

evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for the opinion expressed above. We have not audited the consolidated financial statements of Bindley Western Industries, Inc. for any period subsequent to December 31, 1999.

/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP Indianapolis, Indiana

March 21, 2000, except as to the revision to the financial statements to account for the business combination with Central Pharmacy Services, Inc. as a purchase rather than a pooling of interests and the second paragraph of Note 16 to the consolidated financial statements of Cardinal Health, Inc., which are as of December 15, 2000

10

11

REPORT OF INDEPENDENT ACCOUNTANTS ON FINANCIAL STATEMENT SCHEDULE

To the Board of Directors and Shareholders of Bindley Western Industries, Inc.:

Our audits of the consolidated financial statements referred to in our report dated March 21, 2000, except as to the revision to the financial statements to account for the business combination with Central Pharmacy Services, Inc. as a purchase rather than a pooling of interests and the second paragraph of Note 16 to the consolidated financial statements of Cardinal Health, Inc., which are as of December 15, 2000, appearing in the Cardinal Health, Inc. Form 8-K/A dated February 14, 2001 also included an audit of the Financial Statement Schedule II - Valuation and Qualifying Accounts ("Financial Statement Schedule") of Bindley Western, Industries, Inc. and its subsidiaries (not presented separately herein). In our opinion, this Financial Statement Schedule presents fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated financial statements. We have not audited the consolidated financial statements and Financial Statement Schedule of Bindley Western Industries, Inc. for any period subsequent to December 31, 1999.

/s/ PricewaterhouseCoopers LLP PricewaterhouseCoopers LLP Indianapolis, Indiana

March 21, 2000, except as to the revision to the financial statements to account for the business combination with Central Pharmacy Services, Inc. as a purchase rather than a pooling of interests and the second paragraph of Note 16 to the consolidated financial statements of Cardinal Health, Inc., which are as of December 15, 2000

11

12

CARDINAL HEALTH, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS (In millions, except per share amounts)

		FISCAL YEAR ENDED
	2000	1999
Revenue:		
Operating revenue Bulk deliveries to customer warehouses		\$ 25,682.5 7,050.4
Total revenue	38,349.9	32,732.9
Cost of products sold: Operating cost of products sold Cost of products sold - bulk deliveries Merger-related costs	27,163.8 8,089.9 	22,867.6 7,048.1 4.0
Total cost of products sold	35 , 253.7	29,919.7
Gross margin	3,096.2	2,813.2
Selling, general and administrative expenses	1,751.0	1,697.2
Special charges	64.7	161.4
Operating earnings	1,280.5	954.6
Interest expense and other	138.7	132.9
Earnings before income tax	1,141.8	821.7

JU

Provision for income taxes		424.0		322.4
Net earnings	\$	717.8	\$ ====	499.3
Net earnings per Common Share: Basic Diluted	\$ \$	1.64 1.60	\$ \$	1.14 1.12
Weighted average number of Common Shares outstanding: Basic Diluted		438.8 448.7		434.9 447.2
Net earnings Pro forma adjustment for income taxes (See Note 2)	\$	717.8	\$	499.3
Pro forma net earnings	\$	717.8	\$	490.0
Pro forma net earnings per Common Share: Basic Diluted	\$ \$	1.64 1.60	\$ \$	1.13 1.10

The accompanying notes are an integral part of these consolidated statements.

12

13

CARDINAL HEALTH, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (IN MILLIONS)

	 JUNE 30, 2000
ASSETS	
Current assets:	
Cash and equivalents	\$ 539.5
Trade receivables, net	2,398.8
Current portion of net investment in sales-type leases	187.7
Inventories	4,657.0
Prepaid expenses and other	663.4
Total current assets	 8,446.4

Other assets: Net investment in sales-type leases, less current portion Goodwill and other intangibles, net Other Total LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Notes payable & other short term borrowings Accounts payable Other accrued liabilities Total current liabilities Space of the secure portion Deferred income taxes and other liabilities Shareholders' equity: Common Shares, without par value Retained earnings Common Shares in treasury, at cost Cumulative foreign currency adjustment Other Total shareholders' equity Total shareholders' equity 4,400.4	Property and equipment, at cost: Land, buildings and improvements Machinery and equipment Furniture and fixtures		806.1 2,115.4 144.0
Other assets: Net investment in sales-type leases, less current portion Goodwill and other intangibles, net Other Total Total LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Notes payable & other short term borrowings Accounts payable Other accrued liabilities Total current li			3,065.5 (1,337.2)
Net investment in sales-type leases, less current portion Goodwill and other intangibles, net 1,043.7 Other 227.1 Total Total \$ 12,024.1 Total \$ 12,024.1 Total LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Notes payable & other short term borrowings Accounts payable Other accrued liabilities Total current liabilities Total current liabilities Total current liabilities Total current liabilities S,546.7 Long-term obligations, less current portion Deferred income taxes and other liabilities S52.5 Shareholders' equity: Common Shares, without par value Retained earnings Common Shares in treasury, at cost Cumulative foreign currency adjustment Other Total shareholders' equity Total \$ 12,024.1	Property and equipment, net		
LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Notes payable & other short term borrowings \$ 414.1 Current portion of long-term obligations 9.3 Accounts payable 3,895.1 Other accrued liabilities 1,228.2 Total current liabilities 5,546.7 Long-term obligations, less current portion 1,524.5 Deferred income taxes and other liabilities 552.5 Shareholders' equity: Common Shares, without par value 1,509.6 Retained earnings 3,331.6 Common Shares in treasury, at cost (346.6) Cumulative foreign currency adjustment (81.9) Other (12.3) Total shareholders' equity 4,400.4	Net investment in sales-type leases, less current portion Goodwill and other intangibles, net		
Current liabilities: Notes payable & other short term borrowings Current portion of long-term obligations Accounts payable Other accrued liabilities Total current liabilities Total current liabilities Long-term obligations, less current portion Deferred income taxes and other liabilities Shareholders' equity: Common Shares, without par value Retained earnings Common Shares in treasury, at cost Cumulative foreign currency adjustment Other Total shareholders' equity Total shareholders' equity Total \$ 12,024.1	Total		•
Long-term obligations, less current portion Deferred income taxes and other liabilities Shareholders' equity: Common Shares, without par value Retained earnings Common Shares in treasury, at cost Cumulative foreign currency adjustment Other Total shareholders' equity 1,509.6 (346.6) (346.6) (346.6) (12.3) 7 Total shareholders' equity 4,400.4	Current liabilities: Notes payable & other short term borrowings Current portion of long-term obligations Accounts payable	·	9.3 3,895.1 1,228.2
Deferred income taxes and other liabilities 552.5 Shareholders' equity: Common Shares, without par value 1,509.6 Retained earnings 3,331.6 Common Shares in treasury, at cost (346.6) Cumulative foreign currency adjustment (81.9) Other (12.3) Total shareholders' equity 4,400.4			
Common Shares, without par value 1,509.6 Retained earnings 3,331.6 Common Shares in treasury, at cost (346.6) Cumulative foreign currency adjustment (81.9) Other (12.3) Total shareholders' equity 4,400.4			1,524.5 552.5
, , , , , , , , , , , , , , , , , , , ,	Common Shares, without par value Retained earnings Common Shares in treasury, at cost Cumulative foreign currency adjustment Other		4,400.4
	Total		, -

The accompanying notes are an integral part of these consolidated statements.

13

	COMMO	N SHARES				
	CHADEC		DETAINED	TREASURY		
	SHARES ISSUED	AMOUNT	RETAINED EARNINGS	SHARES	AMOUN	
BALANCE, JUNE 30, 1997	180.5	\$1,121.5	\$1,871.1	(0.8)	\$(34.8	
Comprehensive income: Net earnings Foreign currency translation adjustments			474.3			
Total comprehensive income Employee stock plans activity,						
including tax benefits of \$38.5 million	2.4	79.5		(0.3)	29.0	
Treasury shares acquired and shares retired Dividends paid Adjustment for change in fiscal year	(1.3)	(25.7)	(12.7) (36.8)	(0.9)	(105.6	
of an acquired subsidiary (see Note 1) IPO of subsidiary and related option grant	(0.1)	(0.8) 24.7	(35.0) (5.2)	0.4	25.2	
Shares issued upon conversion of debt Conforming Adjustment (See Note 2) Other	1.5	67.5	(9.7)			
BALANCE, JUNE 30, 1998	183.0	\$1,266.7	\$2,246.0	(1.6)	\$(86.2	
Comprehensive income: Net earnings Foreign currency translation adjustments			499.3			
Total comprehensive income Employee stock plans activity,						
including tax benefits of \$65.4 million	3.4	139.6		(0.7)	34.8	
Treasury shares acquired and shares retired Dividends paid	(1.9)	(73.8)	(2.9) (49.1)	1.7	23.5	
Stock split effected as a stock dividend and cash paid in lieu of fractional shares Adjustment for change in fiscal year	105.6		(0.3)	(0.1)		
of an acquired subsidiary (see Note 1)	0.1	0.5	8.6			
Stock issued for acquisitions and other Distribution of Priority Healthcare Corporation	0.2	(0.1) (24.4)	(1.0) (34.5)			
BALANCE, JUNE 30, 1999 Comprehensive income:	290.4	\$1,308.5	\$2,666.1	(0.7)	\$(27.9	
Net earnings Foreign currency translation adjustments			717.8			
Total comprehensive income Employee stock plans activity,	4.4	147.8			(0.2	
including tax benefits of \$46.9 million Treasury shares acquired and shares retired Dividends paid	4.4	147.0	(22.2) (30.0)	(7.3)	(318.5	
Stock issued for acquisitions and other	4.6	53.3	(0.1)	(0.1)		
BALANCE, JUNE 30, 2000	299.4	\$1,509.6	\$3,331.6	(8.1)	\$(346.	

The accompanying notes are an integral part of these consolidated statements.

14

15

CARDINAL HEALTH INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (IN MILLIONS)

		FISC	AL YEAR
		2000	1
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net earnings	\$	717.8	\$
Adjustments to reconcile net earnings to net cash from	Y	717.0	Ÿ
operating activities:			
Depreciation and amortization		257.0	
Provision for deferred income taxes		127.5	
Provision for bad debts		37.5	
Change in operating assets and liabilities,			
net of effects from acquisitions:			
Increase in trade receivables		(377.3)	
Increase in inventories		(1,071.6)	
Increase in net investment in sales-type leases		(159.5)	
Increase in accounts payable		899.4	
Other operating items, net		73.2	
Net cash provided by operating activities		504.0	
CASH FLOWS FROM INVESTING ACTIVITIES:			
Acquisition/divestiture of subsidiaries, net of cash acquired		(69.6)	
Proceeds from sale of property and equipment		60.2	
Additions to property and equipment		(331.1)	
Purchase of marketable securities available for sale		(7.7)	
Proceeds from sale of marketable securities available for sale		56.1	
Other			
Net cash used in investing activities		(292.1)	
CASH FLOWS FROM FINANCING ACTIVITIES:			

Net change in commercial paper and short-term debt

426.2

Reduction of long-term obligations	(179.8)	
Proceeds from long-term obligations, net of issuance costs	0.5	
Proceeds from securitized borrowings	125.8	
Proceeds from issuance of Common Shares	97.5	
Dividends on common shares, minority interests and		
cash paid in lieu of fractional shares	(30.0)	
Purchase of treasury shares	(341.4)	
Other	0.4	
Net cash provided by/(used in) financing activities	 99.2	
NET INCREASE (DECREASE) IN CASH AND EQUIVALENTS	311.1	
CASH AND EQUIVALENTS AT BEGINNING OF YEAR	 228.4	
CASH AND EQUIVALENTS AT END OF YEAR	\$ 539.5	\$

The accompanying notes are an integral part of these consolidated statements.

15

16

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Cardinal Health, Inc., together with its subsidiaries (collectively the "Company"), is a provider of services to the healthcare industry offering an array of value-added pharmaceutical and other healthcare products distribution services and pharmaceutical-related products and services to a broad base of customers. The Company currently conducts its business within four business segments: Pharmaceutical Distribution and Provider Services; Medical-Surgical Products and Services; Pharmaceutical Technologies and Services; and Automation and Information Services. See Note 12 for discussion related to the Company's operating segments.

BASIS OF PRESENTATION. The consolidated financial statements of the Company include the accounts of all majority-owned subsidiaries and all significant intercompany accounts and transactions have been eliminated. In addition, the consolidated financial statements give retroactive effect to the mergers with MediQual Systems, Inc. ("MediQual") on February 18, 1998; R.P. Scherer Corporation ("Scherer") on August 7, 1998; Allegiance Corporation ("Allegiance") on February 3, 1999; Pacific Surgical Innovations, Inc. ("PSI") on May 21, 1999; Automatic Liquid Packaging, Inc. ("ALP") on September 10, 1999 and Bindley Western Industries, Inc. ("Bindley") on February 14, 2001 (see Note 2). Such

business combinations were accounted for under the pooling-of-interests method.

The Company's fiscal year end is June 30 and Scherer's, PSI's, and Bindley's fiscal year ends were March 31, September 30, and December 31, respectively. For the fiscal year ended June 30, 1998, the consolidated financial statements combine the Company's fiscal year ended June 30, 1998 with Scherer's fiscal year ended March 31, 1998, PSI's fiscal year ended September 30, 1998, and Bindley's fiscal year ended December 31, 1997. For the fiscal years ended June 30, 1999 and 2000, the consolidated financial statements combine the Company's fiscal years ended June 30, 1999 and 2000, with Bindley's fiscal years ended December 31, 1998 and 1999, respectively.

Due to the change in Scherer's fiscal year end from March 31 to conform with the Company's June 30 fiscal year end, Scherer's results of operations for the three months ended June 30, 1998 are not included in the combined results of operations but are reflected as an adjustment in the Consolidated Statements of Shareholders' Equity. Scherer's net revenue and net earnings for this period were \$161.6 million and \$8.6 million, respectively. Scherer's cash flows from operating and financing activities for this period were \$12.6 million and \$32.6 million, respectively, while cash flows used in investing activities were \$12.2 million. As a result of changing Allegiance's fiscal year end from December 31 to June 30, the results of operations for the six months ended December 31, 1997 are included in the combined results of operations for both the fiscal years ended June 30, 1997 and 1998 and are reflected as an adjustment in the Consolidated Statements of Shareholders' Equity. Allegiance's total revenue and net earnings for this period were \$2.2 billion and \$47.9 million, respectively. Allegiance's cash flows from operating activities for this period were \$147.2 million, while cash flows used in investing and financing activities were \$63.7 million and \$83.8 million, respectively. Additionally, as a result of changing Bindley's fiscal year end from December 31 to June 30, Bindley's results of operations for the six months ended June 30, 2000 are not included in the combined results of operations but will be reflected as an adjustment in the Consolidated Statements of Shareholders' Equity. Bindley's net revenue and net earnings excluding special charges were \$4.9 billion and \$22.9 million, respectively. Including special charges for the same period, Bindley's net loss was \$2.8 million. Cash flows from operating activities were \$166.7 million, while cash flows used in investing and financing activities were \$5.7 million and \$113.4 million, respectively.

During fiscal 2000, Bindley completed a merger transaction with Central Pharmacy Services, Inc. ("Central Pharmacy") that was accounted for under the purchase method of accounting. In addition, the Company completed several individually immaterial acquisitions during fiscal 2000, 1999 and 1998, which were accounted for under the purchase method of accounting. The consolidated financial statements include the results of operations from each of these business combinations as of the date of acquisition.

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.

CASH EQUIVALENTS. The Company considers all liquid investments purchased with a maturity of three months or less to be cash equivalents. The carrying value of cash equivalents approximates their fair value. Cash payments for interest were \$133.8 million, \$125.1 million and \$111.5 million and cash payments for income taxes were \$125.5 million, \$94.9 million and \$174.8 million for fiscal 2000, 1999, and 1998, respectively. See Notes 2 and 4 for additional information regarding non-cash investing and financing activities.

16

17

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

RECEIVABLES. Trade receivables are primarily comprised of amounts owed to the Company through its pharmaceutical and other healthcare distribution activities and are presented net of an allowance for doubtful accounts of \$71.1 million and \$61.5 million at June 30, 2000 and 1999, respectively.

The Company provides financing to various customers. Such financing arrangements range from one year to ten years, at interest rates that generally fluctuate with the prime rate. The financings may be collateralized, guaranteed by third parties or unsecured. Finance notes and accrued interest receivable are \$24.0 million and \$19.8 million at June 30, 2000 and 1999, respectively (the current portions are \$9.3 million and \$9.2 million, respectively), and are included in other assets. These amounts are reported net of an allowance for doubtful accounts of \$4.6 million and \$4.9 million at June 30, 2000 and 1999, respectively.

The Company has formed Medicine Shoppe Capital Corporation ("MSCC"), Pyxis Capital Corporation ("PCC") and Cardinal Health Funding LLC ("CHF") as wholly owned subsidiaries of Medicine Shoppe, Pyxis and Griffin Capital Corporation ("Griffin"), respectively. MSCC, PCC and CHF were organized for the sole purpose of buying receivables and selling those receivables to certain financial institutions or to other investors. They are designed to be special purpose, bankruptcy remote entities. Although consolidated to the extent required by generally accepted accounting principles, MSCC, PCC and CHF are separate legal entities from the Company, Medicine Shoppe, Pyxis and Griffin; they each maintain separate financial statements; and their assets will be available first and foremost to satisfy the claims of their creditors.

The Company has formed Bindley Western Funding Corporation ("BWFC") as a wholly owned subsidiary of Bindley. BWFC was organized for the sole purpose of buying receivables and selling those receivables to certain financial institutions or to other investors. Although consolidated to the extent required by generally accepted accounting principles, BWFC is a separate legal entity from the Company and Bindley; it maintains separate financial statements; and its assets will be available first and foremost to satisfy the claims of its creditors.

INVENTORIES. A majority of inventories (approximately 69% in 2000 and 66% in 1999) are stated at lower of cost, using the last-in, first-out ("LIFO") method, or market and are primarily merchandise inventories. The remaining inventory is primarily stated at the lower of cost using the first-in, first-out ("FIFO") method or market. If the Company had used the FIFO method of inventory valuation, which approximates current replacement cost, inventories would have been higher than the LIFO method reported at June 30, 2000 and 1999 by \$57.3 million and \$64.1 million, respectively. Bindley accounted for inventory under the FIFO method prior to the merger transaction with the Company. See Note 2 for discussion of the adjustment to conform Bindley to the LIFO method.

PROPERTY AND EQUIPMENT. Property and equipment are stated at cost. Depreciation and amortization for financial reporting purposes are primarily computed using the straight-line method over the estimated useful lives of the assets which range from one to fifty years, including capital lease assets which are amortized over the terms of their respective leases. Amortization of capital

lease assets is included in depreciation and amortization expense. At each balance sheet date, the Company assesses the recoverability of its long-lived property, based on a review of projected undiscounted cash flows associated with these assets.

GOODWILL AND OTHER INTANGIBLES. Goodwill and other intangibles primarily represent intangible assets related to the excess of cost over net assets of subsidiaries acquired. Intangible assets are being amortized using the straight-line method over lives that range from five to forty years. Accumulated amortization was \$646.2 million and \$607.1 million at June 30, 2000 and 1999, respectively. At each balance sheet date, a determination is made by management to ascertain whether there is an indication that the intangible assets may have been impaired based primarily on a review of projected undiscounted operating cash flows for each subsidiary.

REVENUE RECOGNITION. The Company records distribution revenue when merchandise is shipped to its customers and the Company has no further obligation to provide services related to such merchandise. The Company also acts as an intermediary in the ordering and subsequent delivery of bulk shipments of pharmaceutical products, which are classified as bulk deliveries to customer warehouses and are included in total revenue.

17

18

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Company earns franchise and origination fees from its apothecary-style pharmacy franchisees. Franchise fees represent monthly fees based upon franchisees' sales and are recognized as revenue when they are earned. Origination fees from signing new franchise agreements are recognized as revenue when the new franchise store is opened.

Pharmacy management and other service revenues are recognized as the related services are rendered according to the contracts established. A fee is charged under such contracts through a capitated fee, a dispensing fee, a monthly management fee, or an actual costs-incurred arrangement. Under certain contracts, fees for services are guaranteed by the Company not to exceed stipulated amounts or have other risk-sharing provisions. Revenue is adjusted to reflect the estimated effects of such contractual guarantees and risk-sharing provisions.

Packaging and liquid fill contract manufacturing revenues are recognized from services provided upon the completion of such services.

Drug delivery system revenue is recognized upon shipment of products to the customer. Non-product revenue related to option, milestone and exclusivity fees are recognized when earned and all obligations of performance have been completed.

Revenue is recognized from sales-type leases of point-of-use pharmacy systems when the systems are delivered, the customer accepts the system, and the lease becomes noncancellable. Unearned income on sales-type leases is recognized using the interest method. Sales of point-of-use pharmacy systems are recognized

upon delivery and customer acceptance. Revenue for systems installed under operating lease arrangements is recognized over the lease term as such amounts become receivable according to the provisions of the lease.

Clinical information system license revenue is recognized upon delivery of the software to the customer and the completion of implementation/set up training necessary to operate the software. The portion of the license fee related to system support is deferred and recognized over the annual license period.

TRANSLATION OF FOREIGN CURRENCIES. The financial position and the results of operations of the Company's foreign operations, excluding the Company's Malaysian and Mexican manufacturing operations which are denominated in U.S. dollars, are measured using the local currencies of the countries in which they operate and are translated into U.S. dollars. Although the effects of foreign currency fluctuations are mitigated by the fact that expenses of foreign subsidiaries are generally incurred in the same currencies in which sales are generated, the reported results of operations of the Company's foreign subsidiaries are affected by changes in foreign currency exchange rates and, as compared to prior periods, will be higher or lower depending upon a weakening or strengthening of the U.S. dollar. In addition, the net assets of foreign subsidiaries are translated into U.S. dollars at the foreign currency exchange rates in effect at the end of each period. Accordingly, the Company's consolidated shareholders' equity will fluctuate depending upon the relative strengthening or weakening of the U.S. dollar versus relevant foreign currencies.

DERIVATIVE FINANCIAL INSTRUMENT RISK. The Company uses derivative financial instruments to minimize the impact of foreign exchange rate changes on earnings and cash flows. The Company also periodically enters into foreign currency exchange contracts to hedge certain exposures related to selected transactions that are relatively certain as to both timing and amount. The Company does not use derivative financial instruments for trading or speculative purposes (see Note 5 for further discussion).

RESEARCH AND DEVELOPMENT COSTS. Costs incurred in connection with the development of new products and manufacturing methods are charged to expense as incurred. Research and development expenses, net of customer reimbursements, were \$48.5 million, \$49.7 million, and \$45.7 million in fiscal 2000, 1999, and 1998, respectively. Customer reimbursements in the amount of \$10.4 million, \$11.8 million, and \$13.0 million were received for the fiscal years ended June 30, 2000, 1999, and 1998, respectively.

INCOME TAXES. No provision is made for U.S. income taxes on earnings of foreign subsidiary companies which the Company controls but does not include in the consolidated federal income tax return since it is management's practice and intent to permanently reinvest the earnings.

PRO FORMA ADJUSTMENT FOR INCOME TAXES. On September 10, 1999, the Company completed a merger transaction with ALP (the "ALP Merger"). As of April 1998, ALP had elected S-Corporation status for income tax purposes. As a result of

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

the merger, ALP terminated its S-Corporation election. The pro forma adjustment for income taxes presents the pro forma tax expense of ALP as if ALP had been subject to federal income taxes during the periods presented (see Note 2).

EARNINGS PER COMMON SHARE. Basic earnings per Common Share ("Basic") is computed by dividing net earnings (the numerator) by the weighted average number of Common Shares outstanding during each period (the denominator). Diluted earnings per Common Share is similar to the computation for Basic, except that the denominator is increased by the dilutive effect of stock options, computed using the treasury stock method and in fiscal 1998 by the dilutive effect of Bindley's convertible debentures (\$1.9 million impact on diluted net earnings and an increase of 2.2 million diluted shares). See Note 6 for further discussion of the convertible debentures.

Excluding dividends paid by all entities with which the Company has merged, the Company paid cash dividends per Common Share of 0.667, 0.0633, and 0.0467 for the fiscal years ended June 30, 2000, 1999, and 1998, respectively.

STOCK SPLITS. On August 12, 1998, the Company declared a three-for-two stock split which was effected as a stock dividend and distributed on October 30, 1998 to shareholders of record on October 9, 1998. In addition, on February 27, 2001, the Company declared a three-for-two stock split which was effected as a stock dividend and distributed on April 20, 2001 to shareholders of record on April 5, 2001. All share and per share amounts included in the consolidated financial statements, except the Consolidated Statements of Shareholders' Equity, have been adjusted to retroactively reflect these stock splits.

DISTRIBUTION OF PRIORITY HEALTHCARE CORPORATION. On December 31, 1998, Bindley distributed to the holders of its common stock all of the 10.2 million shares of Priority Healthcare Corporation ("Priority") owned by Bindley. As a result of the distribution, Priority ceased to be a subsidiary of Bindley at the end of fiscal 1999. The dividend distribution of \$58.9 million represents Bindley's ownership interest in the net assets of Priority. The spin-off resulted in the removal of \$107.5 million of assets and \$37.2 million of liabilities from the consolidated balance sheet at the end of fiscal 1999.

NEW ACCOUNTING PRONOUNCEMENT. As of July 1, 1999, the Company adopted the Statement of Position 98-1 ("SOP 98-1"), "Accounting for the Costs of Computer Software Developed or Obtained for Internal Use." SOP 98-1 provides guidance on accounting for costs of computer software developed or obtained for internal use. The adoption of this statement did not have a material impact on the Company's consolidated financial statements.

2. BUSINESS COMBINATIONS, MERGER-RELATED COSTS AND OTHER SPECIAL ITEMS BUSINESS COMBINATIONS. On February 14, 2001 the Company completed a merger transaction with Bindley ("Bindley Merger"), which was accounted for as a pooling-of-interests. In the Bindley Merger, the Company issued approximately 23.1 million Common Shares to Bindley stockholders and Bindley's outstanding stock options were converted into options to purchase approximately 5.1 million Common Shares. The Company recorded a merger-related charge to reflect transaction and other costs incurred as a result of the Bindley Merger in the third quarter of fiscal 2001. Additional merger-related costs associated with integrating the separate companies and instituting efficiencies will be charged to expense in subsequent periods when incurred.

The table below presents a reconciliation of total revenue and net earnings available for Common Shares as reported in the accompanying financial statements

with those previously reported by the Company. The term "Cardinal Health" as used herein refers to Cardinal Health, Inc. and its subsidiaries prior to the Bindley merger transaction.

(in millions)		Cardinal Health Bindley					orming stment
	_				 		
Fiscal year ended June 30, 1998							
Total revenue	\$	21,076.0	\$	7,309.9	\$ 		
Net earnings	\$	448.5	\$	23.7	\$ 2.1		
Fiscal year ended June 30, 1999							
Total revenue	\$	25,111.5	\$	7,621.4	\$ 		
Net earnings	\$	481.0	\$	19.1	\$ (0.8		
Fiscal year ended June 30, 2000							
Total revenue	\$	29,870.6	\$	8,479.3	\$ 		
Net earnings	\$	679.7	\$	36.7	\$ 1.4		

19

20

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Adjustments affecting net earnings and shareholders' equity resulting from the Bindley Merger to adopt the same accounting practices as Cardinal Health related solely to the impact of accounting for Bindley's inventory under the LIFO method, which was previously accounted for under the FIFO method. The beginning balance sheet cumulative adjustment of \$9.7 million is reflected in the Consolidated Statement of Shareholders Equity. There were no material intercompany transactions.

On September 10, 1999, the Company completed the ALP Merger, which was accounted for as a pooling-of-interests. In the ALP Merger, the Company issued approximately 8.7 million Common Shares to ALP stockholders. The Company recorded a merger-related charge to reflect transaction and other costs incurred as a result of the merger transaction during fiscal year 2000.

On August 31, 1999, Bindley completed a merger transaction with Central Pharmacy that was accounted for under the purchase method of accounting. The aggregate purchase price was approximately \$56.7 million, including fees and expenses, which was primarily paid in Bindley common stock. Liabilities assumed were approximately \$16.1 million. Had the acquisition taken place on July 1, 1999, consolidated results would not have been materially different from reported results.

In addition to the merger transactions described above, during fiscal

2000, the Company completed several individually immaterial acquisitions, which were accounted for under the purchase method of accounting. These business combinations were primarily related to the Company's medical-surgical distribution, point-of-use pharmacy systems and pharmaceutical-packaging services. The aggregate purchase price, which was paid primarily in cash, including fees and expenses, was approximately \$63.5 million. Liabilities of the operations assumed were approximately \$7.0 million, including debt of \$4.0 million. Had the acquisitions taken place July 1, 1999, consolidated results would not have been materially different from reported results.

On May 21, 1999, the Company completed a merger transaction with PSI. The Company issued approximately 0.3 million Common Shares to PSI shareholders and has accounted for the merger transaction as a pooling-of-interests in the accompanying financial statements.

On February 3, 1999, the Company completed a merger transaction with Allegiance that was accounted for as a pooling-of-interests transaction. The Company issued approximately 106.1 million Common Shares to Allegiance stockholders and Allegiance's outstanding stock options were converted into options to purchase approximately 15.5 million Common Shares. In addition, on August 7, 1998, the Company completed a merger transaction with Scherer that was accounted for as a pooling-of-interests. The Company issued approximately 51.3 million Common Shares to Scherer stockholders and Scherer's outstanding stock options were converted into options to purchase approximately 5.3 million Common Shares. The Company recorded a merger-related charge to reflect transaction and other costs incurred as a result of these merger transactions in fiscal 1999. Additional merger-related costs associated with integrating the separate companies and instituting efficiencies are charged to expense in subsequent periods when incurred.

In addition to the merger transactions described above, during fiscal 1999, the Company completed several individually immaterial acquisitions, which were accounted for under the purchase method of accounting. These business combinations were primarily related to the Company's medical-surgical distribution, point-of-use pharmacy systems and pharmaceutical-packaging services. The aggregate purchase price, which was paid primarily in cash, including fees and expenses, was approximately \$160.8 million. Liabilities of the operations assumed were approximately \$18.9 million, including debt of \$3.2 million. Had the acquisitions taken place on July 1, 1998, consolidated results would not have been materially different from reported results.

On February 18, 1998, the Company completed a merger transaction with MediQual (the "MediQual Merger") which was accounted for as a pooling-of-interests. The Company issued approximately 1.3 million Common Shares to MediQual shareholders and MediQual's outstanding stock options were converted into options to purchase approximately 0.1 million Common Shares of the Company.

During fiscal 1998, the Company made a number of individually immaterial acquisitions for an aggregate purchase price of \$83.8 million and exchanged non-monetary assets with a value of approximately \$10.5 million to acquire an interest in Source Medical Corporation, a new venture in Canada. All of these acquisitions were accounted for as purchase

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

transactions. Had the acquisitions taken place on July 1, 1997, consolidated results would not have been materially different from reported results.

SPECIAL CHARGES

The following is a summary of the special charges for the fiscal years ended June 30, 2000, 1999 and 1998.

Fiscal	Year	Ended
	June 3	30,

(in millions, except per share amounts)		2000		1999 		1998
Transaction and employee-related costs	\$	(3.8)	\$	(95.4)	\$	(35.7)
ALP transaction bonus		(20.3)				
Exit costs		(11.7)		(9.4)		(3.8)
Scherer restructuring costs		(9.6)		(26.7)		
Inventory write-offs				(4.0)		
Owen Healthcare, Inc. employee-related costs				(1.1)		
Canceled merger transaction				3.7		
Other integration costs		(19.3)		(13.7)		(9.7)
Total merger-related costs	\$	(64.7)	\$	(146.6)	\$	(49.2)
Other special charges:						
Facilities closures	\$		\$		\$	(6.1)
Employee severance						(2.5)
Priority Spin-off				(18.8)		
Total other special charges	\$ 		\$ \$	(18.8)	\$ 	(8.6)
Total special charges	\$	(64.7)	\$	(165.4)	\$	(57.8)
Tax effect of special charges		14.9		33.8		22.0
Tax benefit for change in tax status						11.7
Pro forma ALP taxes		 		9.3		4.6
Net effect of special charges	\$	(49.8)	\$	(122.3)	\$	(19.5)
		40. 11:				
Net effect on diluted earnings per share	\$ =====	(0.11)	\$ ======	(0.27) ======	\$ =====	(0.04)

Merger-Related Charges. Costs of effecting mergers and subsequently integrating the operations of the various merged companies are recorded as merger-related costs when incurred. The merger-related costs are primarily a result of the merger transactions with ALP, Allegiance and Scherer.

During the fiscal years presented in the table herein, the Company incurred direct transaction costs related to its merger transactions. These expenses primarily include investment banking, legal, accounting and other professional fees associated with the respective merger transactions. In addition, the Company incurred employee-related costs, which consist primarily of severance

and transaction/stay bonuses as a result of the ALP, Allegiance and Scherer merger transactions. Partially offsetting the transaction and employee-related costs recorded during the fiscal year ended June 30, 2000 was a \$10.3 million credit to adjust the estimated transaction and employee-related costs previously recorded in connection with the Allegiance merger transaction. Actual billings and employee-related costs were less than the amounts originally anticipated, resulting in a reduction of the merger-related costs. Exit costs relate primarily to costs associated with lease terminations and moving expenses as a direct result of the merger transactions with ALP, Allegiance and Scherer. Other integration costs include charges related to integrating the operations of previous merger transactions.

The Company recorded charges of \$9.6 million and \$26.7 million during the fiscal years ended June 30, 2000 and 1999, respectively, associated with the business restructuring as a result of the Company's merger transaction with Scherer. As part of the business restructuring, the Company is closing certain facilities. In connection with such closings, the

21

22

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Company has incurred employee-related costs, asset impairment charges and exit costs related to the termination of contracts and lease agreements.

Charges of \$4.0 million related to the write-down of impaired inventory associated with the merger transaction with Owen Healthcare, Inc. ("Owen") were recorded during the fiscal year ended June 30, 1999. Also, during fiscal 1999, the Company recorded \$1.1 million related to severance costs for a restructuring associated with the change in management that resulted from the merger transaction with Owen. Partially offsetting the total merger-related charges for fiscal 1999 was a credit recorded to adjust the estimated transaction and termination costs previously recorded in connection with the canceled merger transaction with Bergen Brunswig Corporation ("Bergen") (see Note 15). The actual billings for services provided by third parties engaged by the Company were less than the estimate, resulting in a reduction of the merger-related costs.

Other Special Items. During fiscal 1999, Bindley recorded a special charge of \$18.8 million (\$14.0 million net of tax), of which \$11.0 million related to a non-cash charge for the acceleration of the amortization of compensation related to restricted stock grants in connection with the spin-off of Priority (See Note 1). Approximately \$7.0 million related to write-off of goodwill from an acquisition prior to 1996 and the remaining \$0.8 million represented a legal settlement.

During fiscal 1998, the Company recorded a special charge of \$8.6 million (\$5.2 million net of tax) related to the rationalization of its pharmaceutical distribution operations. Approximately \$6.1 million related to asset impairments and lease exit costs resulting primarily from the Company's decision to accelerate the consolidation of a number of distribution facilities and the relocation to more modern facilities for certain others. The remaining amount related to employee severance costs, including approximately \$2.0 million

incurred in connection with the final settlement of a labor dispute with former employees of the Company's Boston pharmaceutical distribution facility, resulting in termination of the union relationship.

During fiscal 1998, Scherer finalized part of its long-term tax planning strategy by converting, with its joint venture partner, the legal ownership structure of Scherer's 51% owned subsidiary in Germany from a corporation to a partnership. As a result of this change in tax status, the Company's tax basis in the German subsidiary was adjusted, resulting in a one-time tax refund of approximately \$4.6 million, as well as a reduction in cash taxes to be paid in the current and future years. Combined, these factors resulted in a one-time reduction of fiscal 1998 income tax expense by approximately \$11.7 million.

Pro Forma Impact. Since April 1998, ALP had been organized as an S-Corporation for tax purposes. Accordingly, ALP was not subject to federal income tax from April 1998 up to the date of the merger transaction. For the fiscal years ended 1999 and 1998, net earnings would have been reduced by \$9.3 million and \$4.6 million, respectively, if ALP had been subject to federal income taxes.

In fiscal 2000, the net effect of various merger-related charges reduced reported net earnings by \$49.8 million to \$717.8 million and reduced reported diluted earnings per Common Share by \$0.11 per share to \$1.60 per share. The net of tax effect of the various merger-related costs recorded and pro forma adjustments related to ALP taxes during fiscal 1999 was to reduce reported net earnings by \$122.3 million to \$499.3 million and to reduce reported diluted earnings per Common Share by \$0.27 per share to \$1.12 per share. The effect of various merger-related charges and other special items recorded and pro forma adjustments related to ALP taxes during fiscal 1998 was to reduce reported net earnings by \$19.5 million to \$474.3 million and to reduce reported diluted earnings per Common Share by \$0.04 per share to \$1.07 per share.

Certain merger-related costs are based upon estimates, and actual amounts paid may ultimately differ from these estimates. If additional costs are incurred, such items will be expensed as incurred.

22

23

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

3. LEASES

SALES-TYPE LEASES. The Company's sales-type leases are for terms generally ranging up to five years. Lease receivables are generally collateralized by the underlying equipment. The components of the Company's net investment in sales-type leases are as follows (in millions):

June 30, 2000 June 199

Future minimum lease payments receivable Unguaranteed residual values	\$	890.3 11.1	\$
Unearned income		(120.1)	(
Allowance for uncollectible minimum lease payments			
receivable		(15.0)	
Net investment in sales-type leases		766.3	
Less: current portion		187.7	
Net investment in sales-type leases, less current portion	\$	578.6	\$
	====	=======	======

Future minimum lease payments to be received pursuant to sales-type leases during the next five fiscal years and thereafter are: 2001 - \$219.9 million; 2002 - \$214.4 million; 2003 - \$200.6 million; 2004 - \$157.9 million; 2005 - \$85.6 million and 2006 and thereafter - \$11.9 million.

LEASE RELATED FINANCING ARRANGEMENTS. Pyxis has previously financed its working capital needs through the sale of certain lease receivables to a non-bank financing company. As of June 30, 2000, \$22.5 million of lease receivables were owned by the financing company. The agreement with the financing company was amended to terminate Pyxis' obligation to sell lease receivables to the financing company. Due to Pyxis customers upgrading the Pyxis machines or expanding the number of units being leased under the original lease agreements that have been sold to the financing company, Pyxis has been converting the original lease agreements with customers to updated lease agreements. Pyxis has been maintaining these revised leases and not selling them to the financing company to replace the original lease receivables. As a result, Pyxis entered into an agreement with the financing company to pay the financing company the remaining portion of the original lease receivables outstanding at the time of revision over the original terms. The future minimum payments for these notes at June 30, 2000 are: fiscal 2001 - \$36.2 million; fiscal 2002 - \$20.1 million and fiscal 2003 - \$5.4 million, which are classified as part of other liabilities.

4. SHORT-TERM BORROWINGS AND LONG-TERM OBLIGATIONS

NOTES PAYABLE, BANKS. The Company has entered into various unsecured, uncommitted line-of-credit arrangements that allow for borrowings up to \$202.8 million at June 30, 2000, at various money market rates. At June 30, 2000, \$64.1 million, at a weighted average interest rate of 6.2%, was outstanding under such arrangements and \$48.1 million, at a weighted average interest rate of 6.0%, was outstanding at June 30, 1999. The total available but unused lines of credit at June 30, 2000 was \$138.7 million.

SECURITIZED BORROWINGS. Bindley has a receivables securitization facility (the "Receivables Facility") pursuant to which Bindley sells substantially all of its receivables arising in connection with the sale of goods or the rendering of services ("Receivables") to BWFC, a wholly owned special purpose corporation subsidiary (See Note 1). The Receivables are sold to BWFC on a continuous basis, and the cash generated by sales of interests in the Receivables or by collections on the Receivables retained is used by BWFC to, among other things, purchase additional Receivables originated by Bindley. In connection with the Receivables Facility, BWFC entered into an agreement to sell, from time to time, interests in the Receivables ("Receivables Interest") to a third party. Each Receivables Interest has an associated Discount Rate and Tranche Period applicable to it, as selected by BWFC. The Discount Rate is variable based upon corporate prime or LIBOR. At fiscal year end 2000 and 1999, there were \$350.0

million and \$224.2 million of Receivables Interests outstanding bearing a Discount Rate of 6.1% and 5.5% per annum, respectively. The maximum amount of borrowings under this agreement is \$350.0 million. Subsequent to fiscal 2000, this facility has been terminated and all outstanding borrowings have been repaid.

23

24

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

LONG-TERM OBLIGATIONS. Long-term obligations consist of the following (in millions):

		June 30, 2000		•		2000		June 199
6.0% Notes due 2006	\$	150.0	\$					
6.25% Notes due 2008		150.0						
6.5% Notes due 2004		100.0						
6.75% Notes due 2004		99.7						
7.25% Notes due 1999								
7.3% Notes due 2006		127.9						
7.93% Notes due 2004		25.0						
7.8% Debentures due 2016		75.7						
7.0% Debentures due 2026 (7 year put option in 2003)		192.0						
Commercial paper		509.2						
Short-term borrowings, reclassified		54.2						
Borrowings under credit agreement; interest averaging								
6.8% in 1999								
Other obligations; interest averaging 4.6% in 2000 and 6.7% in 1999, due in varying installments								
through 2020		50.1						
Total		1,533.8		1,				
Less: current portion		9.3						
Long-term obligations, less current portion	\$	1,524.5	\$	1,				

The 6.0%, 6.25% and 6.5% Notes represent unsecured obligations of the Company, and the 6.75% Notes represent unsecured obligations of Scherer, which are guaranteed by the Company. The 7.93% and 7.25% Notes represent private placements of unsecured obligations of Bindley. The 7.3% Notes and the 7.8% and 7.0% Debentures represent unsecured obligations of Allegiance, which are guaranteed by the Company. These obligations are not redeemable prior to maturity and are not subject to a sinking fund.

The Company has a commercial paper program, providing on June 30, 2000 for

the issuance of up to \$1.0 billion in aggregate maturity value of commercial paper. The Company had \$509.2 million outstanding under this program at June 30, 2000 with a market interest rate based upon LIBOR. The Company also maintains other short-term credit facilities that allow for borrowings up to \$250.0 million. At June 30, 2000 and 1999, \$54.2 million and \$35.3 million were outstanding under these uncommitted facilities. The effective interest rate as of June 30, 2000 and 1999 was 6.3% and 6.0%, respectively. The Company also has an unsecured bank credit facility, which provides for up to an aggregate of \$1.5 billion in borrowings of which \$750 million expires on March 28, 2002 and \$750 million expires on March 31, 2004. At expiration, these facilities can be extended upon mutual consent of the Company and the lending institutions. This credit facility exists largely to support issuances of commercial paper as well as other short-term borrowings and remained unused at June 30, 2000. At June 30, 2000 and 1999, the commercial paper and other short-term borrowings totaling \$563.4 million and \$84.5 million, respectively, were reclassified as long-term, reflecting the Company's intent and ability, through the existence of the unused credit facility, to refinance these borrowings. Subsequent to June 30, 2000, the Company increased the capacity under its commercial paper program from \$1.0 billion to \$1.5 billion in aggregate maturity value.

During fiscal 1999, the Company issued \$150 million of 6.25% Notes due 2008, the proceeds of which were used for working capital needs due to growth in the Company's business. At June 30, 2000, the Company had the capacity to issue \$250 million of additional debt securities pursuant to a shelf registration statement filed with the Securities and Exchange Commission.

During fiscal 1998, holders of \$65.6 million convertible subordinated debentures, originally issued by Bindley, converted the notes into the equivalent of approximately 2.2 million Common Shares. If the previously mentioned conversion had occurred at the beginning of all periods presented, the changes in diluted earnings per share would not have been material.

24

25

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Certain long-term obligations are collateralized by property and equipment of the Company with an aggregate book value of approximately \$40.9\$ million at June 30, 2000. Maturities of long-term obligations for future fiscal years are: 2001 - \$9.3\$ million; 2002 - \$569.9\$ million; 2003 - \$4.1\$ million; 2004 - \$227.4 million; 2005 - \$2.9 million and 2006 and thereafter - \$720.2 million.

Subsequent to June 30, 2000 the Company entered into an agreement to sell trade receivables to a special purpose accounts receivable and financing entity ("SPE"), which is exclusively engaged in purchasing trade receivables from, and making loans to, the Company. The SPE, which is consolidated by the Company, issued \$400 million in preferred variable debt securities to parties not affiliated with the Company. Those preferred debt securities must be retired or redeemed before the Company can have access to the SPE's receivables.

In addition subsequent to June 30, 2000, the Company issued \$500 million of 6.75% notes due 2011, the proceeds of which were used primarily for early redemption of Bindley debt. After such issuance, the Company has the capacity to

issue approximately \$450 million of additional equity or debt securities pursuant to a shelf registration statement filed with the Securities and Exchange Commission.

5. FINANCIAL INSTRUMENTS

INTEREST RATE MANAGEMENT. The Company has entered into an interest rate swap agreement with a notional amount of \$20.0 million that matures in November 2002 to hedge against variable interest rates. The Company exchanged its variable rate position related to a lease agreement for a fixed rate of 7.08%. The Company recognizes in income the periodic net cash settlements under the swap agreement as it accrues.

Subsequent to June 30, 2000, the Company entered into several interest rate swap agreements with a total notional amount of \$500 million that mature through February 2011 to hedge interest rate exposures related to the \$400 million in preferred debt securities and to hedge the change in fair value of the 6.75% Notes issued subsequent to June 30, 2000.

FOREIGN EXCHANGE RISK MANAGEMENT. In the normal course of business, operations of the Company are exposed to fluctuations in foreign exchange rates. In order to reduce the uncertainty of the impact of foreign exchange rate movements on operations, the Company periodically enters into foreign currency options and forward contracts (principally European currencies and Japanese yen) to hedge certain anticipated sales and firm commitments denominated in foreign currencies. These option and forward contracts typically mature within one year. The Company's forward contracts do not subject it to material risks due to the exchange rate movements because gains and losses on these contracts offset losses and gains on the assets, liabilities, and transactions being hedged. The risk of loss associated with the foreign currency option contracts is limited to the premium paid for the option contracts. Gains and losses on the forward and option contracts are recognized concurrently with the gains and losses from the underlying transactions. Premiums paid on the option contract are amortized in other income/expense over the life of the underlying hedged transactions.

The Company also uses commodity contracts to hedge raw material costs expected to be denominated in foreign currency. These contracts generally cover a one-year period and all gains and losses are deferred and recognized in cost of goods sold with the underlying product costs. The contracts qualify as hedges for accounting purposes in accordance with the criteria established in SFAS No. 80 "Accounting for Futures Contracts." Cash flows resulting from these commodity contracts are classified in the same category as the items being hedged.

The counterparties to these contracts are major financial institutions and the Company does not have significant exposure to any one counterparty. Management believes the risk of loss is remote and in any event would not be material.

FAIR VALUE OF FINANCIAL INSTRUMENTS. The carrying amounts of cash and equivalents, trade receivables, accounts payable, notes payable-banks, securitized borrowings and other accrued liabilities at June 30, 2000 and 1999, approximate their fair value because of the short-term maturities of these items.

The estimated fair value of the Company's long-term obligations was \$1,494.6 million and \$1,263.9 million as compared to the carrying amounts of \$1,533.8 million and \$1,266.1 million at June 30, 2000 and 1999, respectively. The fair value of the Company's long-term obligations is estimated based on either the quoted market prices for the same or similar issues and the current interest rates offered for debt of the same remaining maturities or estimated discounted cash flows.

25

26

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The following is a summary of the fair value gain/(loss) of the Company's derivative instruments, based upon the estimated amount that the Company would receive (or pay) to terminate the contracts as of June 30. The fair values are based on quoted market prices for the same or similar instruments.

(in millions)

	2000		1999		
	Notional	Fair Value	Notional	Fair Value	
	Amount	Gain/(Loss)	Amount	Gain/(Loss	
Foreign currency forward contracts Commodity contracts	\$ 17.2	\$ 0.1	\$ -	\$ -	
	\$ 3.9	\$ 0.1	\$ 9.6	\$ (0.3)	
Interest Rate Swaps	\$ 20.0	\$ -	\$ 20.0	\$ (0.7)	

6. INCOME TAXES

Consolidated earnings before income taxes (in millions)

	Fiscal Year Ended June 30,					
	2000		1999		1998 	
U.S. Based Operations Non-U.S. Based Operations	\$	1,016.3 125.5	\$	747.3	\$	625.2
	\$	1,141.8		821.7	·	734.3

The provision for income taxes consists of the following (in millions):

2000		-	1999			1998	
	Fiscal	Year	Ended	June	30 ,		

	=====		====		====	
Total provision	\$	424.0	\$	322.4	\$	260.0
Deferred		128.5		128.3		87.5
Total	\$	295.5	\$	194.1	\$	172.5
Foreign		28.3		21.7		15.8
State		25.2	'	29.4	'	25.8
Current: Federal	\$	242.0	\$	143.0	\$	130.9

A reconciliation of the provision based on the Federal statutory income tax rate to the Company's effective income tax rate is as follows:

Fiscal Year Ende	d June 30,
Fiscal Year Ende	d June 30,

	2000	1999	1998
Provision at Federal			
Statutory rate	35.0%	35.0%	35.0%
State income taxes, net of			
Federal benefit	3.1	4.0	4.1
Foreign tax rates	(2.1)	(2.9)	(4.5)
Nondeductible expenses	1.3	4.6	1.4
Other	(0.2)	(1.5)	(0.6)
Effective income tax rate	37.1%	39.2%	35.4%
	==========	=========	========

Provision has not been made for U.S. or additional foreign taxes on \$303.2 million of undistributed earnings of foreign subsidiaries because those earnings are considered permanently reinvested in the operations of those subsidiaries. It is not practicable to estimate the amount of tax that might be payable on the eventual remittance of such earnings.

26

27

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Deferred income taxes arise from temporary differences between financial reporting and tax reporting bases of assets and liabilities, and operating loss and tax credit carryforwards for tax purposes. The components of the deferred income tax assets and liabilities are as follows (in millions):

		June 30, 2000		
Deferred income tax assets: Receivable basis difference Accrued liabilities Net operating loss carryforwards Foreign tax and other credit carryforwards Other	\$	45.1 39.0 8.6 10.5 9.5	\$	34 103 9 16 38
Total deferred income tax assets	\$	112.7	\$	202
Valuation allowance for deferred income tax assets		(2.7)		(7
Net deferred income tax assets	\$	110.0	\$	195
Deferred income tax liabilities: Inventory basis differences Property-related Revenues on lease contracts Other		(175.1) (207.1) (178.7) (13.9)		
Total deferred income tax liabilities	\$	(574.8)	\$	(520
Net deferred income tax liabilities		(464.8)		(325

The above amounts are classified in the consolidated balance sheets as follows (in millions):

	June 30, 2000			June 199 	
Other current assets/(liabilities) Deferred income taxes and other liabilities	\$	(106.7) (358.1)	\$	9 (42	
Net deferred income tax liabilities	\$ =====	(464.8)	\$ ===	(32	

The Company had Federal net operating loss carryforwards of \$3.4 million and state net operating loss carryforwards of \$166.9 million at June 30, 2000. A valuation allowance of \$2.7 million at June 30, 2000 has been provided for the state net operating loss, as utilization of such carryforwards within the applicable statutory periods is uncertain. The Company's Federal net operating loss carryforwards and a portion of the state net operating loss carryforwards are subject to a change in ownership limitation calculation under Internal Revenue Code Section 382. After application of the valuation allowance described above, the Company anticipates no limitations will apply with respect to

utilization of these assets. The Federal net operating loss carryforward begins expiring in 2005 and the state net operating loss carryforward expires through 2020. Expiring state net operating loss carryforwards and the required valuation allowances have been adjusted annually. At June 30, 2000, the Company did not have any foreign tax credit carryforwards.

Under a tax-sharing agreement with Baxter International, Inc. ("Baxter"), Allegiance will pay for increases and be reimbursed for decreases to the net deferred tax assets transferred on the date of the Baxter spin-off of Allegiance. Such increases or decreases may result from audit adjustments to Baxter's prior period tax returns.

7. EMPLOYEE RETIREMENT BENEFIT PLANS

The Company sponsors various retirement and pension plans, including defined benefit and defined contribution plans. Substantially all of the Company's domestic non-union employees are eligible to be enrolled in Company-sponsored contributory profit sharing and retirement savings plans, which include features under Section 401(k) of the InternalRevenue Code, and provide for Company matching and profit sharing contributions. The Company's contributions to the plans are determined by the Board of Directors subject to certain minimum requirements as specified in the plans.

27

28

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Qualified domestic union employees are covered by multi-employer defined benefit pension plans under the provisions of collective bargaining agreements. Benefits under these plans are generally based on the employee's years of service and average compensation at retirement.

The total expense for employee retirement benefit plans (excluding defined benefit plans (see below)) was as follows (in millions):

	Fiscal Year Ended June 3						
	2000		 1 		199 		
Defined contribution plans Multi-employer plans	\$	42.8 0.4	\$	46.1 0.5	\$		
Total	\$ =====	43.2	\$	46.6	\$		

DEFINED BENEFIT PLANS. The Company has several defined benefit plans covering substantially all salaried and hourly Scherer employees. The Company's domestic defined benefit plans provide defined benefits based on years of service and level of compensation. Foreign subsidiaries provide for pension benefits in accordance with local customs or law. The Company funds its pension plans at

amounts required by the applicable regulations.

The following tables provide a reconciliation of the change in benefit obligation, the change in plan assets and the net amount recognized in the consolidated balance sheets (based on a measurement date of March 31, in millions):

	June 30,			
	2000		1999	
Change in benefit obligation: Benefit obligation at beginning of year Service cost Interest cost Plan participant contributions	\$	98.7 4.6 5.7 0.5	\$	6.5 6.7 0.7
Amendments Actuarial loss Benefits paid Translation and other adjustments Curtailments		6.1 (2.8) (12.5) (0.3)		0.2 4.6 (3.7) (3.0)
Benefit obligation at end of year	\$	100.0	\$	98.7
Change in plan assets: Fair value of plan assets at beginning of year Actual return on plan assets Employer contributions Plan participant contributions Benefits paid Translation and other adjustment	\$	55.7 6.3 3.5 0.5 (2.3) 1.2	\$	42.2 12.2 4.9 0.7 (2.6) (1.7)
Fair value of plan assets at end of year	\$	64.9	\$	55.7

28

29

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30,

	2000			1999
Funded status	\$	(35.1) 8.0	\$	(43.0) 7.5
Unrecognized net actuarial loss Unrecognized net transition		8.0		7.5
asset		(0.4)		(2.0)
Unrecognized prior service cost		0.2		0.2
Translation and other adjustment		0.5		
Net amount recognized	\$	(26.8)	\$	(37.3)
	====	======	====	======
Amounts recognized in the Consolidated Balance Sheets:				
Prepaid benefit cost	\$		\$	1.6
Accrued benefit liability		(26.8)		(38.9)
Net amount recognized	\$	(26.8)	\$	(37.3)
	====	======	====	======

The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for the pension plans with accumulated benefit obligations in excess of plan assets were \$98.7 million, \$94.9 million, and \$63.5 million, respectively, as of June 30, 2000 and \$89.4 million, \$85.1 million and \$47.8 million, respectively, as of June 30, 1999.

Components of the Company's net periodic benefit costs are as follows (in millions):

		For th	e Fiscal	Year Ended	June 30,
		2000		1999	 19
Components of net periodic					
benefit cost:					
Service cost	\$	4.6	\$	6.5	\$
Interest cost		5.7		6.7	
Expected return on plan assets		(6.2)		(6.9)	
Amortization of actuarial loss		0.1		1.9	
Amortization of transition obligation		1.9			
Amortization of prior service cost				0.3	
Net amount recognized	\$	6.1	\$	8.5	\$
	=====		=====		=====

For fiscal 2000 and 1999, the weighted-average actuarial assumptions used in determining the funded status information and net periodic benefit cost information were: discount rate of 6.5% and 6.4%, expected return on plan assets of 7.4% and 6.2% and rate of compensation increase of 4.0% and 3.7%, respectively.

8. COMMITMENTS AND CONTINGENT LIABILITIES

The future minimum rental payments for operating leases having initial or remaining non-cancelable lease terms in excess of one year at June 30, 2000 are:

fiscal 2001 - \$50.0 million; fiscal 2002 - \$36.9 million; fiscal 2003 - \$29.7 million; fiscal 2004 - \$24.9 million; fiscal 2005 - \$19.7 million and fiscal 2006 and thereafter - \$36.2 million.

In addition, the Company has entered into operating lease agreements with several banks for the construction of various new facilities. The initial terms of the lease agreements extend through May 2005, with optional five-year renewal periods. In the event of termination, the Company is required to either purchase the facility or vacate the property and make reimbursement for a portion of unrecovered property cost. The instruments provide for maximum fundings of \$406.2 million, which is the total estimated cost of the construction projects. As of June 30, 2000, the amount expended was \$279.9 million. As of June 30, the Company's minimum annual lease payments under the agreements are approximately

29

30

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

\$18.8 million. Neither the facilities' cost or the minimum annual lease payments are included in the future minimum rental payments disclosed above.

Rental expense relating to operating leases was approximately \$76.1 million, \$71.9 million, and \$66.9 million in fiscal 2000, 1999 and 1998, respectively. Sublease rental income was not material for any period presented herein.

As of June 30, 2000, the Company has capital expenditure commitments related primarily to plant expansions and facility acquisitions of approximately \$21.8 million.

On September 30, 1996, Baxter International Inc. ("Baxter") and its subsidiaries transferred to Allegiance and its subsidiaries their U.S. healthcare distribution business, surgical and respiratory therapy business and healthcare cost-saving business, as well as certain foreign operations (the "Allegiance Business") in connection with a spin-off of the Allegiance Business by Baxter. In connection with this spin-off, Allegiance, which was acquired by the Company on February 3, 1999, agreed to indemnify certain claims related to the Allegiance Business from Baxter Healthcare Corporation ("BHC"), including certain claims of alleged personal injuries as a result of exposure to natural rubber latex gloves. Allegiance will be defending and indemnifying BHC, as contemplated by the agreements between Baxter and Allegiance, for all expenses and potential liabilities associated with claims pertaining to the litigation assumed by Allegiance. As of March 31, 2001, there were approximately 600 lawsuits involving BHC and/or Allegiance containing allegations of sensitization to natural rubber latex products. Some of the cases are now proceeding to trial. Because of the increase in claims filed and the ongoing defense costs that will be incurred, the Company believes it is probable that it will continue to incur significant expenses related to the defense of cases involving natural rubber latex gloves. At this time, the Company is unable to evaluate the extent of any potential liability, and unable to estimate any potential loss. AEIA, one of the insurers for the latex glove litigation, has advised the Company of its intent to resolve through arbitration the extent of its obligation to reimburse the Company for certain defense costs and loss expenses incurred in connection with the litigation. The Company believes a substantial portion of any liability will

be covered by insurance, subject to self-insurance retentions, exclusions, conditions, coverage gaps, policy limits and insurer solvency.

The Company also becomes involved from time-to-time in other litigation incidental to its business, including without limitation inclusion of certain of its subsidiaries as a potentially responsible party for environmental clean-up costs. Although the ultimate resolution of the litigation referenced herein cannot be forecast with certainty, the Company intends to vigorously defend itself and currently does not believe that the outcome of any pending litigation will have a material adverse effect on the Company's consolidated financial statements.

9. SHAREHOLDERS' EQUITY

At June 30, 2000 and 1999, the Company's authorized capital shares consisted of (a) 500,000,000 Class A common shares, without par value; (b) 5,000,000 Class B common shares, without par value; and (c) 500,000 non-voting preferred shares without par value. The Class A common shares and Class B common shares are collectively referred to as Common Shares. Holders of Class A and Class B common shares are entitled to share equally in any dividends declared by the Company's Board of Directors and to participate equally in all distributions of assets upon liquidation. Generally, the holders of Class A common shares are entitled to one vote per share and the holders of Class B common shares are entitled to one-fifth of one vote per share on proposals presented to shareholders for vote. Under certain circumstances, the holders of Class B common shares are entitled to vote as a separate class. Only Class A common shares were outstanding as of June 30, 2000 and 1999.

On November 1, 2000, the shareholders of the Company approved, and the Company's articles of incorporation were amended to effect, an increase in the number of authorized Class A common shares, without par value from 500 million to 750 million.

On March 16, 2000, the Company's Board of Directors authorized the repurchase of Common Shares up to an aggregate amount of \$750 million of Common Shares. Through June 30, 2000, approximately 7 million Common Shares, having an aggregate cost of \$302.8, had been repurchased under an accelerated share repurchase program and placed into treasury shares. As of June 30 2000 all shares repurchased under the program were subject to a future contingent purchase price adjustment to be settled based upon the difference in the market price of the Company's common stock at the time of settlement compared to the market price as of March 16, 2000. Subsequent to June 30, 2000, the transaction was settled for an additional \$137.4 million, which was charged to common shares in treasury. The Company's Board of Directors rescinded the remainder of this repurchase program in November 2000.

30

31

CARDINAL HEALTH, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Subsequent to June 30, 2000, the Company issued 750,000 Common Shares for which it received aggregate proceeds of \$47.7 million, which were used for general corporate purposes. The Common Shares were issued in order for the Company to be able to satisfy all of the conditions to consummation of the Bindley Merger (see Note 2).

10. CONCENTRATIONS OF CREDIT RISK AND MAJOR CUSTOMERS

The Company invests cash in deposits with major banks throughout the world and in high quality short-term liquid instruments. Such investments are made only in instruments issued or enhanced by high quality institutions. These investments mature within three months and the Company has not incurred any related losses.

The Company's trade receivables, finance notes and accrued interest receivable, and lease receivables are exposed to a concentration of credit risk with customers in the retail and healthcare sectors. Credit risk can be affected by changes in reimbursement and other economic pressures impacting the acute care portion of the healthcare industry. However, such credit risk is limited due to supporting collateral and the diversity of the customer base, including its wide geographic dispersion. The Company performs ongoing credit evaluations of its customers' financial conditions and maintains reserves for credit losses. Such losses historically have been within the Company's expectations.

During fiscal 2000, 1999 and 1998, the Company's two largest customers individually accounted for 10% and 11% of operating revenue, respectively. These two customers are serviced primarily through the Pharmaceutical Distribution and Provider Services and Medical-Surgical Products and Services segments. During fiscal 2000, three customers individually accounted for 42%, 30%, and 16% of bulk deliveries, respectively. These three customers accounted for 19%, 29% and 18% of bulk deliveries during fiscal 1999, respectively. During fiscal 1998, four customers accounted for 24%, 22%, 18%, and 15% of bulk deliveries, respectively.

11. STOCK OPTIONS AND RESTRICTED SHARES

The Company maintains stock incentive plans (the "Plans") for the benefit of certain officers, directors and employees. Options granted generally vest over two or three years and are exercisable for periods up to ten years from the date of grant at a price which equals fair market value at the date of grant.

The Company accounts for the Plans in accordance with APB Opinion No. 25, under which no compensation cost has been recognized. Had compensation cost for the Plans been determined consistent with Statement of Financial Accounting Standards No. 123 ("SFAS 123"), "Accounting for Stock-Based Compensation," the Company's net income and diluted earnings per Common Share would have been reduced by \$24.7 million and \$0.06 per share, respectively, for fiscal 2000, \$86.4 million and \$0.19 per share, respectively, for fiscal 1999, and \$36.1 million and \$0.08 per share, respectively, for fiscal 1998. During fiscal 1999, stock option grants under the previous Allegiance and Scherer plans vested immediately on the merger date. These accelerated grants increased